ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2013
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06584435 (A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.Cancer science · 2017Trial
- Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- Effects of Metformin on JNK Signaling Pathway and PD-L1 Expression in Triple Negative Breast Cancer.Cancer management and research · 2024Article
- The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions.Journal of cancer research and clinical oncology · 2023Article
- High Expression of Tumor HLA-DR Predicts Better Prognosis and Response to Anti-PD-1 Therapy in Laryngeal Squamous Cell Carcinoma.Translational oncology · 2023Article
- Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint.Scientific reports · 2023Article
- Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer.Thoracic cancer · 2023Review
- Identifying key transcription factors and immune infiltration in non-small-cell lung cancer using weighted correlation network and Cox regression analyses.Frontiers in oncology · 2023Article
- A small molecule inhibitor of VSIG-8 prevents its binding to VISTA.Investigational new drugs · 2022Article
- IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.Biomarker research · 2022Review
- Tumor Microenvironment Characterization in Breast Cancer and an Immune Cell Infiltration Score Development, Validation, and Application.Frontiers in oncology · 2022Article
- Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.BMC immunology · 2021Article
- Review
- Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.Diagnostics (Basel, Switzerland) · 2021Article
- Structural Basis of VSIG3: The Ligand for VISTA.Frontiers in immunology · 2021Article
- Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.Journal for immunotherapy of cancer · 2020Article
- Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.Scientific reports · 2020Article
- Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis.Systematic reviews · 2020Article
- Current Status of Immunotherapy for Lung Cancer and Future Perspectives.Tuberculosis and respiratory diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatments of non-small-cell lung cancer (NSCLC)-particularly of the squamous subtype-are limited. In this article, we describe the immunomodulatory environment in NSCLC and the potential for therapeutic targeting of the immune system through cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) immune-checkpoint pathway blockade. MATERIALS AND
methodsWe searched PubMed and presented abstracts for publications describing the clinical benefit of checkpoint blockade in NSCLC.
resultsAntibody-mediated checkpoint molecule blockade is being investigated in NSCLC, and of these approaches, the anti-CTLA-4 antibody ipilimumab has undergone the most extensive clinical study. By targeting the immune system rather than specific antigens, checkpoint blockade agents differ from vaccine therapy. In a phase II study in advanced NSCLC, phased ipilimumab with chemotherapy demonstrated the greatest efficacy in squamous NSCLC. A phase I study of nivolumab, an anti-PD-1 antibody, has suggested that this agent is also active against squamous and non-squamous NSCLC. Ongoing phase III studies are evaluating the therapeutic potential of these agents.
conclusionsAlthough treatment options for NSCLC are limited, a better understanding of the immune profile of this disease has facilitated the development of immunotherapeutics that target checkpoint blockade molecules, and clinical evaluation to date supports combining checkpoint blockade with chemotherapy for squamous NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.